Abstract:Background: The heart grows in response to pathological and physiological stimuli. The former often precedes cardiomyocyte loss and heart failure; the latter paradoxically protects the heart and enhances cardiomyogenesis. The mechanisms underlying these differences remain incompletely understood. Although long noncoding RNAs (lncRNAs) are important in cardiac development and disease, less is known about their roles in physiological hypertrophy or cardiomyogenesis. Methods: RNA sequencing was applied to hearts from mice after 8 weeks of voluntary exercise-induced physiological hypertrophy and cardiomyogenesis or transverse aortic constriction for 2 or 8 weeks to induce pathological hypertrophy or heart failure. The top lncRNA candidate was overexpressed in hearts with adeno-associated virus vectors and inhibited with antisense locked nucleic acid-GapmeRs to examine its function. Downstream effectors were identified through promoter analyses and binding assays. The functional roles of a novel downstream effector, dachsous cadherin-related 2 (DCHS2), were examined through transgenic overexpression in zebrafish and cardiac-specific deletion in Cas9-knockin mice. Results: We identified exercise-regulated cardiac lncRNAs, called lncExACTs. lncExACT1 was evolutionarily conserved and decreased in exercised hearts but increased in human and experimental heart failure. Cardiac lncExACT1 overexpression caused pathological hypertrophy and heart failure; lncExACT1 inhibition induced physiological hypertrophy and cardiomyogenesis, protecting against cardiac fibrosis and dysfunction. lncExACT1 functioned by regulating microRNA-222, calcineurin signaling, and Hippo/Yap1 signaling through DCHS2. Cardiomyocyte DCHS2 overexpression in zebrafish induced pathological hypertrophy and impaired cardiac regeneration, promoting scarring after injury. In contrast, murine DCHS2 deletion induced physiological hypertrophy and promoted cardiomyogenesis. Conclusions: These studies identify lncExACT1-DCHS2 as a novel pathway regulating cardiac hypertrophy and cardiomyogenesis. lncExACT1-DCHS2 acts as a master switch toggling the heart between physiological and pathological growth to determine functional outcomes, providing a potentially tractable therapeutic target for harnessing the beneficial effects of exercise.

LIM and Cysteine-Rich Domains 1 Regulates Cardiac Hypertrophy by Targeting Calcineurin/Nuclear Factor of Activated T Cells Signaling

Transcriptional Upregulation of Calcineurin Aβ by Endothelin-1 is Partially Mediated by Calcium/calmodulin-Dependent Protein Kinase IIδ3 in Rat Cardiomyocytes

NFATc4 and Myocardin Synergistically Up-Regulate the Expression of LTCC Α1c in ET-1-induced Cardiomyocyte Hypertrophy.

Ca²⁺ Signal-Induced Cardiomyocyte Hypertrophy Through Activation of Myocardin.

Inhibition of Histone Demethylase JMJD1C Attenuates Cardiac Hypertrophy and Fibrosis Induced by Angiotensin II

[Role of Bcl-2 Transcriptional Regulation Induced by Calmodulin I Pressure Overload Rat Hypertrophic Hearts].

Myeloid MKL1 Disseminates Cues to Promote Cardiac Hypertrophy in Mice

Microrna-1 Negatively Regulates Expression of the Hypertrophy-Associated Calmodulin and Mef2a Genes

Calcineurin Enhances MAPK Phosphatase-1 Expression and p38 MAPK Inactivation in Cardiac Myocytes

Low density lipoprotein receptor-related protein 1 regulates cardiac hypertrophy induced by pressure overload

The δA isoform of calmodulin kinase II mediates pathological cardiac hypertrophy by interfering with the HDAC4-MEF2 signaling pathway.

Myocardin-Related Transcription Factor-A Induces Cardiomyocyte Hypertrophy

lncExACT1 and DCHS2 Regulate Physiological and Pathological Cardiac Growth

Abstract P234: CTMP Negatively Regulates Pathological Cardiac Hypertrophy via Akt-dependent Manner

Calponin1 Inhibits Dilated Cardiomyopathy Development in Mice Through the Εpkc Pathway.

High-mobility group box 1 induces calcineurin-mediated cell hypertrophy in neonatal rat ventricular myocytes.

Cip, A Cardiac Isl1-Interacting Protein, Represses Cardiomyocyte Hypertrophy

Nuclear Receptor Corepressor 1 Represses Cardiac Hypertrophy

Carboxyl-Terminal Modulator Protein Ameliorates Pathological Cardiac Hypertrophy by Suppressing the Protein Kinase B Signaling Pathway.

Lactate Dehydrogenase A Governs Cardiac Hypertrophic Growth in Response to Hemodynamic Stress

Abstract 65: Regulation of Cardiac Hypertrophy and Dilated Cardiomyopathy by CIP